|
|
Background: This study aimed to identify the diagnostic and prognostic ability of serum miR-411-3p in patients with acute myeloid leukemia (AML).
Methods: Blood samples were collected from 60 AML patients and 60 healthy controls to measure serum miR-411-3p and thereafter discuss its potential clinical value.
Results: Serum miR-411-3p was decreased in AML patients and was even lower in those with M4/M5 subtypes or high white blood cell count or adverse cytogenetic risk. Serum miR-411-3p had a diagnostic value. An association existed between low serum miR-411-3p and worse clinical features and shorter survival, and miR-411-3p was able to predict overall survival and relapse-free survival in AML patients. In addition, serum miR-411-3p was upregulated after treatment, especially in AML patients who achieved complete remission.
Conclusions: Serum miR-411-3p is of promising utility regarding AML diagnosis and prognosis.
DOI: 10.7754/Clin.Lab.2025.250149
|
